MRK Merck
Data as of close
Dow Jones CompaniesS&P 500 Companies
Healthcare · Pharmaceutical Preparations
Merck (MRK) is a healthcare company in the Pharmaceutical Preparations industry, with a market capitalization of $356.9 billion. Shares last traded at $144.67, 7.8% below their 52-week high. Over the past year the stock is up 68.0%. MRK trades at a price-to-earnings ratio of 112.49, above the Pharmaceutical Preparations median of 15.73. Net profit margin is 4.8%, above the peer median of -7.4%. Revenue grew 1.3% year over year. The shares yield 2.3% in dividends.
* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.
Performance
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
Financials
Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-06-30. Source: SEC EDGAR/XBRL.
MRK Dividend History
| Fiscal year end | Total dividends paid | Per share* | Payout ratio |
|---|---|---|---|
| 2025-12-31 | $8.18B | $3.26 | 45% |
| 2024-12-31 | $7.84B | $3.09 | 46% |
| 2023-12-31 | $7.45B | $2.92 | 2040% |
| 2022-12-31 | $7.01B | $2.76 | 48% |
| 2021-12-31 | $6.61B | $2.60 | 54% |
| 2020-12-31 | $6.21B | $2.45 | 88% |
| 2019-12-31 | $5.70B | $2.21 | 58% |
| 2018-12-31 | $5.17B | $1.93 | 83% |
| 2017-12-31 | $5.17B | $1.88 | 216% |
| 2016-12-31 | $5.12B | $1.84 | 131% |
| 2015-12-31 | $5.12B | $1.80 | 115% |
| 2014-12-31 | $5.17B | $1.77 | 43% |
*Per share derived as total dividends paid ÷ weighted diluted shares (SEC EDGAR/XBRL annual cash-flow facts). Reported history — not a forecast of future dividends.
Compare payers on the highest-dividend-yield screener.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q2 2026 | -$0.54 | 2026-08-07 |
| Q1 2026 | -$1.72 | 2026-05-04 |
| Q4 2025 (derived) | $1.19 | 2026-02-24 |
| FY 2025 | $7.28 | 2026-02-24 |
| Q3 2025 | $2.32 | 2025-11-05 |
| Q2 2025 | $1.76 | 2025-08-05 |
Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.
Pharmaceutical Preparations peers
MRK vs 14 industry peers (Pharmaceutical Preparations), by market cap. Data as of close
| LLY | Lilly (Eli) | $1.33T | 48.07 | 15.33 | 31.9% | -0.12% |
| JNJ | Johnson & Johnson | $640.8B | 39.81 | 6.45 | 16.2% | -1.76% |
| ONC | Beone Medicines Ltd. | $524.6B | 800.05 | 85.59 | 10.7% | -1.72% |
| ABBV | AbbVie | $503.8B | 48.71 | 7.63 | 15.7% | -1.30% |
| MRK | Merck | $356.9B | 112.49 | 5.36 | 4.8% | -2.57% |
| ABT | Abbott Laboratories | $190.6B | 30.37 | 4.22 | 13.9% | -0.78% |
| PFE | Pfizer | $171.2B | 42.46 | 2.69 | 6.3% | -2.18% |
| VRTX | Vertex Pharmaceuticals | $134.7B | 33.87 | 10.40 | 30.7% | -6.81% |
| BMY | Bristol Myers Squibb | $126.1B | 13.65 | 2.52 | 18.5% | -2.09% |
| REGN | Regeneron Pharmaceuticals | $100.7B | 20.91 | 5.96 | 28.5% | +1.30% |
| TEVA | Teva Pharmaceutical Industries Ltd | $48.9B | 96.62 | 2.84 | 2.9% | +3.00% |
| ZTS | Zoetis | $34.3B | 13.11 | 3.60 | 27.5% | -0.18% |
| RPRX | Royalty Pharma Plc | $29.5B | 36.25 | 11.65 | 32.1% | -0.26% |
| ROIV | Roivant Sciences Ltd. | $26.0B | — | 3458.17 | — | +0.47% |
🇨🇦 Merck also trades on Cboe Canada as a CAD-hedged Canadian Depositary Receipt (CDR) under MRK. A CDR represents the same underlying MRK shares in Canadian dollars with the currency exposure hedged; this page tracks the US-listed shares.
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.